Fifteen patients with rheumatoid arthritis received indomethacin in three treatment schedules; indomethacin retard 75 mg twice daily; indomethacin capsules 50 mg three times daily; and indomethacin 100 mg suppository at night with 50 mg by mouth each morning. The study was a double-blind, double-dummy one with each treatment being given for 2 weeks after a washout period of 3 days. After the washout period, and at the end of each 2 week active treatment period, blood samples were taken during a dosage interval for assay of indomethacin concentrations in plasma. Clinical assessments were also performed. All three treatment periods produced significant clinical improvements in the assessments compared with the placebo washout period. However, no differences were seen between the treatments. Side effects occurred with equal frequency in all three periods, and the anticipated reduction in central nervous system side effects during the indomethacin retard period was not seen. Plasma concentrations of indomethacin were significantly higher during indomethacin retard therapy with a peak concentration of 2500 + 25 ng ml-' during indomethacin retard therapy (mean + s.d.) and 1900 ± 200 ng ml 'during conventional oral therapy. Indomethacin retard is as effective as the other formulations of indomethacin but appears to offer no significant advantages.
Introduction
Indomethacin has been used in the treatment of rheumatoid arthritis for more than 10 years. The drug is commonly given in a three times daily schedule primarily lecause it has a relatively short plasma halflife. Recently, a sustained release formulation of indomethacin (Indocid ®d ) has been marketed which is said to be effective in a twice daily dosing schedule. We have undertaken a study to compare the clinical effects and pharmacokinetics of Indocid® with other formulations of indomethacin in patients with rheumatoid arthritis.
Methods
Fifteen patients with definite or classical rheumatoid arthritis (Ropes et al., 1959) were chosen for study. Four patients were male, eleven were female and their ages ranged from 51 to 70 years with a mean age 0306-5251/82/080286-04 $01.00 of 56.4 years. All patients were known previously to have improved on indomethacin therapy and no patient was receiving gold, penicillamine, corticosteroids or chloroquine or had received them in the previous year. The study received ethical approval from the local hospital ethics committee and after it had been explained to the patients their written informed consent was obtained. All previous antiinflammatory therapy was then withdrawn (indomethacin in 11 patients, naproxen in 3 and flurbiprofen in 1), and following a 3 day washout period during which only paracetamol or Distalgesic therapy was allowed, patients were randomly allocated to one of three treatment schedules for 2 weeks. Each patient received 150 mg indomethacin daily as either (a) Indocid(® 75 mg twice daily, (b) indomethacin capsules 50 mg three times daily or (c) indomethacin 100 mg suppository at 23.00 h with an oral 50 mg dose at 08.00 h, using a double-dummy technique. After the first 2 week treatment period each patient received the two alternative active treatment schedules for 2 weeks each in random order. Paracetamol or Distalgesic tablets were issued to each patient for escape analgesia. At the end of the washout period, and at the end of each 2 week treatment period, clinical assessments were performed between 11.00 h and 12.00 h by the same observer on each occasion (K.R.H.A.) The clinical assessments included (Baber et al., 1980) : (1) Overall global assessment (2) Comparative global assessment (3) The duration of morning stiffness (4) Pain score using an analogue scale 10 cm long.
(The patients were allowed access to their previous pain score records.) (5) Articular index of joint tenderness (Ritchie et al., 1968 ). (6) Digital joint size (Boardman & Hart, 1967) (7) Grip strength (8) The number of paracetamol tablets (or Distalgesic tablets) used in each period was counted and used as a further index of clinical improvement. At the end of each visit each patient was weighed and questioned about unwanted effects. Side effects were noted on a volunteered or elicited basis; these included headache, dizziness, confusion, drowsiness (CNS effects), epigastric discomfort, nausea, vomiting, diarrhoea, rectal irritation and tenesmus (gastrointestinal effects).
Blood samples were taken on each visit to measure the haemoglobin concentration, the white cell count and the erythrocyte sedimentation rate (ESR). Blood (10 ml) was also taken at 10.00 h, 12.00 h, 14.00 h and 16.00 h into lithium heparin and centrifuged at 2000 rev/min prior to storage of the plasma at -20°C. Blood samples were also taken at 20.00 h in patients during the Indocid®) period only. In six patients blood was taken at 08.00 h to see if the plasma indomethacin concentration was the same as at 16.00 h or 20.00 h for Indocid(® (pre-dosing blood samples). These plasma samples were analysed for their indomethacin concentration using a gas liquid chromatographic assay (Sibeon et al., 1979) .
Statistical methods
The area under the plasma indomethacin versus time curve (AUC) was measured by the trapezoidal rule over a dosage interval (8 h for standard indomethacin, 12 h for Indocid(9 ). In the first six patients the plasma indomethacin concentration at 08.00 h was not significantly different from the value at 16.00 h. In all the other patients, therefore, the value at 16.00 h or 20.00 h for Indocid¢) was taken as the concentration at zero time. The steady-state plasma indomethacin concentration (C,,) was calculated from the AUC where S= AUC/y where y is the dosage interval in hours.
The plasma half-life of indomethacin was calculated by least squares regression analysis of the terminal exponential phase of the plasma indomethacin concentration profile.
The Wilcoxon sign sum rank test was used to analyse changes between the various treatment periods and also to compare these with the initial washout period.
Results
All fifteen patients completed the study. Compliance with the protocol was good as judged by returned capsule counts. During the washout period an increase in the clinical indices was seen indicating worsening of disease activity.
The results of the clinical assessments are shown in Table 1 .
The articular index and duration of morning stiffness improved significantly in all three treatment periods, while the pain score improved significantly in the Indocid® and oral indomethacin treatment periods. Grip strength improved significantly only in the Indocid® period. There were no significant differences between the three treatment periods.
There were no significant changes in weight, haemoglobin, white cell count or ESR during the study.
Patient comments
Patients were asked which treatment period they preferred at the end of the study; eight patients said they preferred the Indocid®(f period, three preferred the conventional oral treatment period, two preferred the suppository period and two had no preference (P > 0.1) No order or period effects were noted in the study.
Side effects
Side effects were seen with equal frequency in all three treatment periods. Four patients volunteered headaches in the Indocid® period (while a further six were elicited) compared to three (+3 elicited) in the oral indomethacin period and two (+2 elicited in the suppository period. There was no evidence that evidence that headaches were more common shortly after dosing with indomethacin. Lightheadedness was noted in three patients (volunteered + elicited) in the Indocid® period, in five patients in the oral treatment period and in four patients in the supposit- Steady-state 12 plasma concentration (AUC/y) (ng ml-l) Peak indomethacin 25 concentration (ng ml-') 2 Time to peak plasma concentration (h) Plasma half-life (h) ory period. Rectal irritation was only noted in three patients in the suppository period, while other gastrointestinal symptoms (nausea or indigestion) were commented on six occasions in the Indocid(® period and on eight occasions in both the standard oral treatment period and the suppository period.
Plasma indomethacin concentrations
The results of the plasma indomethacin concentration analyses are shown in 
Discussion
Indocid(® consists of 25 mg conventional indomethacin wrapped around a core of 50 mg indomethacin in a sustained release preparation. It was introduced to allow twice daily dosing and has been shown to be as effective as conventional indomethacin in a number of studies (Schlemmer & Braun, 1978; Fasching & Erbel, 1979; Raman et al., 1980; Iversen et al., 1981) . The study reported here is in agreement with these observations and, like them, shows that Indocid(® has no advantage over the conventional formulations of indomethacin. The number of patients studied, however, is probably too small to detect minor differences between the formulations.
In this study, peak concentrations of indomethacin were significantly higher in the Indocid(® group than in the conventional indomethacin group (see Table 2) in contrast to an earlier study (Vignon & Chapuy, 1979) . When the figures were corrected for the dose of indomethacin given, the peak concentrations were very similar. The only evidence of efficacy of the slow release preparation was a slightly later peak concentration and a larger plasma half-life of indomethacin. We had hoped that an efficient sustained release preparation might reduce the incidence of headaches and lightheadedness since these symptoms are often associated with high peak concentrations of indomethacin (Turakka & Airaksinen, 1974; Alvan et al., 1975) . However, no such reduction was seen. While Indocid(® is effective clinically it has no obvious advantages over current formulations of indomethacin. An improved formulation of
